Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc Stock (PYXS) dropped by 2.58% from $1.55 to $1.51 in the trading on Tuesday November 28, 2023. The reason why PYXS stock down today is due to the announcement of CMO appointment. Pyxis Oncology announced the appointment of Ken Kobayashi as Chief Medical Officer, effective November 27, 2023. As CMO, Kobayashi will lead the company’s clinical and regulatory operations, drive strategic growth, and play a key role in advancing Pyxis Oncology’s clinical pipeline.

Pyxis Oncology Inc Stock (PYXS) dropped by 10.46% from $3.73 to $3.34 in the trading on Wednesday May 24, 2023. The reason why PYXS stock down today is due to the announcement of Apexigen acquisition. Pyxis Oncology has agreed to acquire Apexigen (APGN) in an all-stock deal valued at approximately $16 million. The deal will combine Pyxis Oncology's FACT ADC platform with Apexigen's APXiMAB platform, creating a leading ADC development company with a pipeline of promising clinical candidates. Under the terms of the deal, Apexigen shareholders will receive 0.1725 shares of Pyxis Oncology common stock for each share of Apexigen they own. The deal is expected to close in the fourth quarter of 2023.